Is Beta Drugs a Good Buy After Its Q1 FY27 Results?
- September 9, 2026
- Posted by: Harsh Piplani
- Category: Market
Beta Drugs share price around Rs 2,113. 24.7% below 52-week high of Rs 2,808. Q1 FY27 revenue Rs 127 crore, up 23.2% YoY. PAT Rs 16 crore, up 40.9%. PE 51x.
Quick Answer
Beta Drugs’ Q1 FY27 results were strong, with revenue at Rs 127 crore and PAT climbing 41% to Rs 16 crore. The stock trades at a PE of 51x against an industry average near 38x, so some of this good news is already priced in. The Beta Drugs share price near Rs 2,113 reflects that optimism, so investors weighing whether Beta Drugs is a good buy today should focus on whether this pace of growth can be sustained rather than just this quarter’s print.
The Beta Drugs share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Beta Drugs is a manufacturer of oncology injectables and specialty formulations, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.
Revenue for the quarter came in at Rs 127 crore, up 23.2% year on year, while profit after tax came in at Rs 16 crore, up 40.9% from a year earlier. That combination of numbers is exactly what this article breaks down, along with what it means for the Beta Drugs share price from here.
This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the Beta Drugs share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.
Click Here – Get Free Investment Predictions
Beta Drugs Q1 FY27 Financial Highlights
| Metric | Q1 FY27 | Q1 FY26 | YoY Change |
|---|---|---|---|
| Revenue | Rs 127 crore | Rs 103 crore | 23.2% |
| EBITDA | Rs 29 crore | Rs 23 crore | 27.5% |
| Operating Margin | 23.1% | 22.6% | NA |
| Profit Before Tax | Rs 22 crore | Rs 16 crore | 40.9% |
| Net Profit / (Loss) | Rs 16 crore | Rs 12 crore | 40.9% |
Beta Drugs Q1 FY27 Performance Analysis
Check Beta Drugs Fundamentals on Univest Screener
Revenue growth of 23.2% for the quarter came from steady demand across the company’s core business, keeping the topline trend intact for the oncology injectables manufacturing sector.
The bigger story is on profitability. PAT grew 41% to Rs 16 crore, comfortably ahead of revenue growth, which points to margin expansion or a favourable base effect. This is the kind of quarter that supports the premium the Beta Drugs share price already commands, though investors should check whether the growth is repeatable or was helped by one-off factors.
On a sequential basis, revenue moved up 31.3% sequentially from Rs 97 crore in the March 2026 quarter and net profit moved up 82.2% sequentially from Rs 9.05 crore in the prior quarter, giving a fuller picture of the trend behind the Beta Drugs share price than the year on year comparison alone.
Key Business Factors in Q1 FY27
Revenue Trend
Beta Drugs’ revenue grew 23.2% year on year this quarter, taking the quarterly base to Rs 127 crore in an oncology injectables manufacturing business that remains sensitive to demand and pricing cycles that ultimately feed through to the Beta Drugs share price.
Margin Movement
EBITDA rose 27.5% to Rs 29 crore, and operating margin moved to 23.1% from 22.6% a year earlier, a sign that cost control or pricing held up during the quarter.
Balance Sheet Position
Beta Drugs’ debt-to-equity ratio stands at 0.60, a level worth monitoring given the quarter’s margin trend.
Valuation Context
The stock trades at a PE of 51.3x against an industry average of 38.0x, a premium that this quarter’s results will need to justify going forward.
Dividend Details
No interim dividend was declared alongside Beta Drugs’ Q1 FY27 results. The stock has not paid a meaningful dividend in the trailing twelve months. Investors tracking the Beta Drugs share price for income should watch the company’s announcements around its next annual results for any dividend decision.
Beta Drugs Share Price Outlook for FY27
The Q1 FY27 print sets a reasonably high bar for the rest of the year. If Beta Drugs can sustain this pace of revenue and profit growth, the current valuation gets easier to justify. The main swing factor is whether this quarter’s momentum reflects a durable trend or a favourable one-off, something the next two quarters should clarify.
For the Beta Drugs share price to hold its current premium through FY27, the company will likely need to keep posting growth at or near this quarter’s pace, since any slowdown would put pressure on a stock priced for continued strength.
Beta Drugs Stock Performance
Download the Univest iOS App or Univest Android App to track Beta Drugs’ live share price and get daily stock updates.
The Beta Drugs share price was trading around Rs 2,113 as results season played out in late August 2026, roughly 24.7% below its 52-week high of Rs 2,808 and well above its 52-week low of Rs 990.
The Beta Drugs share price has room to re-rate further if the growth shown this quarter continues, though much of the good news may already be reflected in the stock near current levels. On profitability ratios, the company reports a return on equity of 16.95% and a book value of around Rs 222 per share, both useful reference points when judging whether the current price is reasonable.
Key Risks
Valuation Risk
At 51.3x earnings against an industry average of 38.0x, the stock leaves little room for disappointment if growth slows.
Leverage Risk
A debt-to-equity ratio of 0.60 means the company’s earnings are more sensitive to interest rate and refinancing conditions than a lower-debt peer.
Sector and Demand Risk
As an oncology injectables manufacturing business, Beta Drugs’ results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Beta Drugs share price well before the next result.
Conclusion
Beta Drugs’ Q1 FY27 results were genuinely strong, with revenue at Rs 127 crore and PAT up 41% to Rs 16 crore. That said, at a PE of 51.3x, the Beta Drugs share price is not inexpensive, so this looks like a quality business trading at a full price rather than a bargain. Existing investors have little to worry about from this print, while new investors asking whether Beta Drugs is a good buy should weigh the strong quarter against the valuation before adding at current levels.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Beta Drugs Q1 FY27 Results
What were Beta Drugs’ Q1 FY27 results?
Ans. Beta Drugs reported Q1 FY27 revenue of Rs 127 crore, up 23.2% year on year, and PAT of Rs 16 crore, up 40.9% year on year.
Is Beta Drugs a good buy after its Q1 FY27 results?
Ans. Beta Drugs’ core numbers improved this quarter, though at a PE of 51.3x the stock is not inexpensive, so this suits investors comfortable paying up for quality. Investors should form their own view based on their own risk appetite and time horizon.
What is the Beta Drugs share price today?
Ans. The Beta Drugs share price was trading around Rs 2,113 in late August 2026, about 24.7% below its 52-week high of Rs 2,808 and well above its 52-week low of Rs 990.
What is Beta Drugs’ revenue and profit for Q1 FY27?
Ans. Beta Drugs reported revenue of Rs 127 crore and a net profit of Rs 16 crore for the quarter ended June 30, 2026.
Did Beta Drugs declare a dividend with its Q1 FY27 results?
Ans. No interim dividend was declared alongside Beta Drugs’ Q1 FY27 results. Investors should track the company’s next annual results for any dividend announcement.
What is Beta Drugs’ PE ratio and is it expensive?
Ans. The Beta Drugs share price trades at a trailing PE of 51.3x, against an industry average of 38.0x. Investors should compare this with the company’s growth rate before judging value.
What are the key risks for Beta Drugs investors right now?
Ans. At 51.3x earnings against an industry average of 38.0x, the stock leaves little room for disappointment if growth slows. As an oncology injectables manufacturing business, Beta Drugs’ results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Beta Drugs share price well before the next result.
What is Beta Drugs’ promoter shareholding?
Ans. Promoter shareholding data for Beta Drugs was not fully available for this quarter and should be checked on the company’s official filings.
